Patrícia Silva, PhD, director of science content —

Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by Patrícia Silva

PAH Review Finds Combination Therapy Superior to Monotherapy in Reducing Clinical Worsening

The use of a combination therapy in patients with pulmonary arterial hypertension (PAH) “significantly” reduced the risk of clinical worsening compared to monotherapy in those responding to treatment, according to a recent meta-analysis published in the journal The Lancet, titled “Combination therapy versus monotherapy for pulmonary arterial hypertension:…

Experimental PH Treatment, Ubenimex, Recognized as Orphan Drug by EMA in Advance of Clinical Study

Eiger BioPharmaceuticals recently announced that its protease inhibitor ubenimex has been granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of pulmonary arterial hypertension (PAH). The company will soon begin a Phase 2 clinical trial testing ubenimex in this patient group. The EMA designation covers…

Pulmonary Rehab of Multiple Benefit to People with PH and Other Respiratory Diseases, Release Notes

Pulmonary rehabilitation has been shown to significantly improve the quality of life of those affected by lung diseases, including chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis (IPF), or pulmonary hypertension (PH), a University of Kentucky news release reported. But what, exactly, is pulmonary rehabilitation? The American Association of…

First PAH Patients Treated with TIVUS Catheter System in Initial Clinical Trial

SoniVie recently announced that it has completed the first two procedures in an initial clinical trial evaluating TIVUS system (Therapeutic Intra-Vascular Ultrasound) for the treatment of pulmonary arterial hypertension (PAH). TIVUS is a therapeutic catheter inserted into the pulmonary artery to selectively damage nerves associated with PAH disease activity, without touching vessel walls…

Potential PAH Treatment, a Soluble Guanylate Cyclase Stimulator, Will Advance in Testing Based on Phase 1a Trial Results

Ironwood Pharmaceuticals, Inc. recently announced positive top-line results from a Phase 1a clinical trial of IW-1701, an investigational soluble guanylate cyclase (sGC) stimulator that is part of the pharmacologically distinct library of sGC compounds discovered by Ironwood. An enzyme, sGC is crucial to the physiological control of blood flow, inflammation, and fibrosis.

New PAH Drug, Uptravi, Moves Step Closer to Approval in Europe

Action Pharmaceuticals recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion on the use of Uptravi (selexipag) for the treatment of patients with a diagnosis of pulmonary arterial hypertension (PAH). Uptravi is an oral IP prostacyclin receptor agonist.